

Resource Summary Report

Generated by [NIF](#) on Jul 28, 2026

CONFIRM anti-CD3 (2GV6) Rabbit Monoclonal Primary Antibody

RRID:AB_2335978

Type: Antibody

Proper Citation

Ventana Medical Systems Cat# 790-4341, RRID:AB_2335978

Antibody Information

URL: http://antibodyregistry.org/AB_2335978

Proper Citation: Ventana Medical Systems Cat# 790-4341, RRID:AB_2335978

Target Antigen: CD3

Host Organism: rabbit

Clonality: monoclonal

Comments: Used By NYUIHC-743

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE

Antibody Name: CONFIRM anti-CD3 (2GV6) Rabbit Monoclonal Primary Antibody

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: 2GV6

Antibody ID: AB_2335978

Vendor: Ventana Medical Systems

Catalog Number: 790-4341

Alternative Catalog Numbers: 05278422001

Record Creation Time: 20250819T210130+0000

Record Last Update: 20250819T213602+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for CONFIRM anti-CD3 (2GV6) Rabbit Monoclonal Primary Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 41 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Bechter O, et al. (2025) A Phase I, First-in-Human, Dose-Escalation, Expansion Trial of Cytokine-Encoding Synthetic mRNA Mixture Alone or with Cemiplimab in Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(12), 2358.

Saidoune F, et al. (2025) Enhanced TLR7-dependent production of type I interferon by pDCs underlies pandemic chilblains. The Journal of experimental medicine, 222(7).

Kunika MD, et al. (2025) m276-SL-PBD eradicates tumors and instigates long-lasting tumor-free survival in Merkel cell carcinoma preclinical models. iScience, 28(5), 112436.

Sacco JJ, et al. (2025) Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecific. Cell reports. Medicine, 6(4), 102076.

Munoz-Couselo E, et al. (2025) Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma. Cancer research communications, 5(2), 358.

Kim S, et al. (2025) Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer. iScience, 28(2), 111736.

Ersoy M, et al. (2025) Discordance in Immunohistochemistry Results in Breast Pathologies: Effect of Chemotherapy, Specimen Characteristics, or Pathology Center?

Clinical Medicine Insights. Oncology, 19, 11795549251367498.

Donati B, et al. (2024) Spatial Distribution of Immune Cells Drives Resistance to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. *Cancer immunology research*, 12(1), 120.

Sun Y, et al. (2024) Integrated multi-omics profiling to dissect the spatiotemporal evolution of metastatic hepatocellular carcinoma. *Cancer cell*, 42(1), 135.

Li Y, et al. (2024) Multimodal immune phenotyping reveals microbial-T cell interactions that shape pancreatic cancer. *Cell reports. Medicine*, 5(2), 101397.

Toh J, et al. (2024) Multi-modal analysis reveals tumor and immune features distinguishing EBV-positive and EBV-negative post-transplant lymphoproliferative disorders. *Cell reports. Medicine*, 5(12), 101851.

De Sanctis F, et al. (2024) Expression of the membrane tetraspanin claudin 18 on cancer cells promotes T lymphocyte infiltration and antitumor immunity in pancreatic cancer. *Immunity*, 57(6), 1378.

Zhang C, et al. (2024) Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104). *Cell reports. Medicine*, 5(7), 101615.

Hansen AR, et al. (2024) Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(24), 5540.

Radtke AJ, et al. (2024) Multi-omic profiling of follicular lymphoma reveals changes in tissue architecture and enhanced stromal remodeling in high-risk patients. *Cancer cell*, 42(3), 444.

Campbell MJ, et al. (2024) Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer. *Cell reports. Medicine*, 5(11), 101799.

Tabata M, et al. (2023) Inter- and intra-tumor heterogeneity of genetic and immune profiles in inherited renal cell carcinoma. *Cell reports*, 42(7), 112736.

Pouyabahar D, et al. (2023) A rat liver cell atlas reveals intrahepatic myeloid heterogeneity. *iScience*, 26(11), 108213.

Egan H, et al. (2023) Targeting stromal cell sialylation reverses T cell-mediated immunosuppression in the tumor microenvironment. *Cell reports*, 42(5), 112475.

Yanagawa J, et al. (2023) Single-Cell Characterization of Pulmonary Nodules Implicates Suppression of Immunosurveillance across Early Stages of Lung Adenocarcinoma. *Cancer research*, 83(19), 3305.